University of Cagliari   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Cagliari Italy (1606)

Organization Overview

First Clinical Trial
1998
NCT00755859
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

A.O.U. di Cagliari | A.O.U. di Cagliari - Presidio di Monserrato | Azienda Sanitaria Locale di Cagliari | Cagliari University | Department of biomedical sciences University of Cagliari, Italy | Department of Internal Medicine, University of Cagliari-Italy | Dept. Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy | Hospital G. Brotzu, Cagliari, Italy | Ospedale A. Businco, Cagliari | Ospedale Businco di Cagliari | Ospedale Regionale Microcitemie, Cagliari | Ospedale Regionale Microcitemie, Cagliari, Italy | Presidio Ospedaliero R. Binaghi, Cagliari | Presidio Ospedaliero R. Binaghi, Cagliari - Italy | University of Cagliari | University of Cagliari, Department of Medical Sciences and Public Health

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Amenorrhea (Phase 4)

beta-Thalassemia (Phase 4)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Cardiomyopathies (Phase 4)

Endometriosis (Phase 4)

Glomerulonephritis, IGA (Phase 4)

Heart Diseases (Phase 4)

Hemosiderosis (Phase 4)

Iron Overload (Phase 4)

Kidney Diseases (Phase 4)

Leiomyoma (Phase 4)

Lung Neoplasms (Phase 2)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, Large B-Cell, Diffuse (Phase 2)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Neoplasms, Plasma Cell (Phase 2)

Preleukemia (Phase 3)

Stomach Neoplasms (Phase 3)

Syndrome (Phase 3)

Thalassemia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 15
  • # of Trial APIs: 28